The U.S. Food and Drug Administration has approved the use of ustekinumab, marketed as Stelara, for treating pediatric patients with moderate to severe ulcerative colitis. This marks an important development in expanding therapeutic options for young patients dealing with this chronic inflammatory condition.

Ustekinumab, which was previously approved for adults with ulcerative colitis, now holds a labeled indication that includes pediatric patients. This approval provides healthcare professionals with an additional treatment avenue to help manage disease symptoms in this vulnerable group.

The FDA's decision is based on an evaluation of the drug's safety and efficacy profile, supporting its use as a treatment for moderate to severe cases of pediatric ulcerative colitis. This expansion in the drug's label reflects ongoing efforts to address unmet medical needs in pediatric populations.